Research programme: influenza vaccine - Akela Pharma

Drug Profile

Research programme: influenza vaccine - Akela Pharma

Latest Information Update: 18 Mar 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nventa Biopharmaceuticals Corporation
  • Developer Akela Pharma
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Influenza virus infections

Most Recent Events

  • 18 Mar 2013 9147415 - Akela Pharma no longer operating, no indication development was even ongoing at the time they went bankrupt as they'd turned to focus on Formulation Technologies, which was more of a CRO
  • 14 Mar 2013 Akela Pharma and its subsidiaries cease operations
  • 14 Mar 2013 Discontinued - Preclinical for Influenza virus infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top